Literature DB >> 12751049

The role of carnitine in normal and altered fatty acid metabolism.

Charles Hoppel1.   

Abstract

Carnitine is a low-molecular-weight compound obtained from the diet that also is biosynthesized from the essential amino acids lysine and methionine. Carnitine has been identified in a variety of mammalian tissues and has an obligate role in the mitochondrial oxidation of long-chain fatty acids through the action of specialized acyltransferases. Other roles for carnitine include buffering of the acyl coenzyme A (CoA)-CoA ratio, branched-chain amino acid metabolism, removal of excess acyl groups, and peroxisomal fatty acid oxidation. The growing body of evidence about carnitine function has led to increased understanding and identification of disorders associated with altered carnitine metabolism. Disorders of fatty acid oxidation and metabolism typically are associated with primary and secondary forms of carnitine deficiency. These disorders, which include increased lipolysis, increased lipid peroxidation, accumulation of acylcarnitines, and altered membrane permeability, have significant consequences for patients with myocardial diseases and kidney failure. Therapeutic administration of carnitine shows promise in treating selected groups of patients who have altered carnitine homeostasis, resulting in improved cardiac function, increased exercise capacity, reduced muscle cramps, and reduced intradialytic complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751049     DOI: 10.1016/s0272-6386(03)00112-4

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  77 in total

Review 1.  Advances in genetics: what are the benefits for patients?

Authors:  A Munnich
Journal:  J Med Genet       Date:  2005-12-09       Impact factor: 6.318

Review 2.  The use of levo-carnitine in children with renal disease: a review and a call for future studies.

Authors:  Brook Belay; Nora Esteban-Cruciani; Christine A Walsh; Frederick J Kaskel
Journal:  Pediatr Nephrol       Date:  2005-12-23       Impact factor: 3.714

3.  Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis.

Authors:  Enrico Verrina; Ubaldo Caruso; Maria Grazia Calevo; Francesco Emma; Palma Sorino; Tommaso De Palo; Giancarlo Lavoratti; Laura Turrini Dertenois; Michela Cassanello; Roberto Cerone; Francesco Perfumo
Journal:  Pediatr Nephrol       Date:  2007-02-03       Impact factor: 3.714

4.  Hypolipidemic effect of dietary water-soluble protein extract from chicken: impact on genes regulating hepatic lipid and bile acid metabolism.

Authors:  Rita Vik; Bodil Bjørndal; Pavol Bohov; Trond Brattelid; Asbjørn Svardal; Ottar K Nygård; Jan E Nordrehaug; Jon Skorve; Rolf K Berge
Journal:  Eur J Nutr       Date:  2014-04-23       Impact factor: 5.614

5.  Pre-exercise medium-chain triglyceride application prevents acylcarnitine accumulation in skeletal muscle from very-long-chain acyl-CoA-dehydrogenase-deficient mice.

Authors:  Sonja Primassin; Sara Tucci; Diran Herebian; Annette Seibt; Lars Hoffmann; Frank ter Veld; Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2010-05-06       Impact factor: 4.982

Review 6.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

7.  SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE).

Authors:  Chunyu Wang; Ivan P Uray; Abhijit Mazumdar; Julie Ann Mayer; Powel H Brown
Journal:  Breast Cancer Res Treat       Date:  2012-01-03       Impact factor: 4.872

8.  Differential mobility spectrometry (DMS) reveals the elevation of urinary acetylcarnitine in non-human primates (NHPs) exposed to radiation.

Authors:  Nicholas B Vera; Zhidan Chen; Evan Pannkuk; Evagelia C Laiakis; Albert J Fornace; Derek M Erion; Stephen L Coy; Jeffrey A Pfefferkorn; Paul Vouros
Journal:  J Mass Spectrom       Date:  2018-07       Impact factor: 1.982

9.  Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies.

Authors:  Sook Wah Yee; Dina Buitrago; Adrian Stecula; Huy X Ngo; Huan-Chieh Chien; Ling Zou; Megan L Koleske; Kathleen M Giacomini
Journal:  FASEB J       Date:  2020-10-30       Impact factor: 5.191

10.  Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation.

Authors:  Rainer Lehmann; Xinjie Zhao; Cora Weigert; Perikles Simon; Elvira Fehrenbach; Jens Fritsche; Jürgen Machann; Fritz Schick; Jiangshan Wang; Miriam Hoene; Erwin D Schleicher; Hans-Ulrich Häring; Guowang Xu; Andreas M Niess
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.